CAS: 92134-98-0; Sodium (2,5-Dioxo-4,4-Diphenylimidazolidin-1-yl)Methyl Phosphate

该化合物是苯丁胺钠的一种杂草,主要用于对缉获进行管理,特别是在诸如癫痫等紧急情况下;是一种水溶性化合物,有助于对苯丁胺酮进行静脉注射,而没有与后者溶解性和配方有关的并发症; 磷苯丁钠的特征是其迅速转化为体内的苯丁胺,允许采取有效的治疗行动; 化合物一般是作为钠盐施用,以增强其溶解性和生物利用率; 其化学结构包括一个磷酸盐类,有助于其溶解性特征; 磷酸钠一般是经过良好调味的,但与所有药物一样,它可能具有副作用,包括眩晕,眩晕和潜在的过敏反应; 必须在治疗过程中监测病人的不良影响和治疗效果; 总的来说, 氟苯丁钠是苯丁钠作为苯丁胺酮的重要替代品,特别是在急性护理环境中.

结构式图片

欧盟法规

C&L通报REACH预注册

合成工艺路线路线简述

  • 21616-46-6 = 92134-98-0
    反应条件:1.1 Reagents: Triethylamine,1H-1,2,4-Triazole Solvents: Dichloromethane; Rt -> 10 °C1.2 Reagents: Phosphorus Oxychloride; 0 - 10 °C; 1 H,0 - 10 °C1.3 1 H,0 - 10 °C1.4 Reagents: Sodium Bicarbonate Solvents: Water; Ph 7.5 - 8.0; 1 H,0 - 10 °C
    标题:Preparation Process Of Fosphenytoin Sodium
    参考文献:China]

    93390-81-9 = 92134-98-0
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; Rt1.2 Reagents: Acetone Solvents: Methanol; 65 °C; Overnight,Cooled
    标题:Synthesis Of Fosphenytoin
    作者:Jin,Xueping
    参考文献:Huaxue Yu Shengwu Gongcheng 日期:2007 卷标:24(12) 页码:56-57]

    93360-08-8 = 92134-98-0
    反应条件:1.1 Reagents: Sodium Formate Catalysts: Palladium Solvents: Methanol; Ph 10 - 11,Rt -> 302 °C
    标题:Preparation Of 5,5-Diphenyl-3-[(Phosphonoxy)Methyl]-2,4-Imidazolidinedione Disodium Salt
    参考文献:Brazil]

    93360-08-8 = 92134-98-0
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium,Carbon Solvents: Ethyl Acetate; Rt1.2 Reagents: Sodium Hydroxide Solvents: Methanol,Water; Rt
    标题:Process For The Preparation Of Sodium Fosphenytoin
    参考文献:United States]

    93360-08-8 = 92134-98-0
    反应条件:1.1 Reagents: Sodium Acetate,Hydrogen Catalysts: Palladium,Carbon Solvents: Acetic Acid,Methanol,Water; 2.5 H,Ph 8.5,1.5 - 2.5 Atm,40 °C
    标题:Method For Producing Sodium Fosphenytoin
    参考文献:World Intellectual Property Organization]

    93360-08-8 = 92134-98-0
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 2 H,3 - 3.5 Kg/cm2,25 °C1.2 Reagents: Sodium Hydroxide Solvents: Acetone,Water; Rt
    标题:Novel Synthesis Of Fosphenytoin. Anti-Convulsant Prodrug
    作者:Elati,Chandrashekar R.; Gangula,Srinivas; Naredla,Anitha; Ashok,S.; Bhattacharya,Apurba; Et Al
    参考文献:Synthetic Communications 日期:2008 卷标:38(17) 页码:2950-2957]

    93390-81-9 = 92134-98-0
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 10 Min,Rt; 30 Min,Rt
    标题:Method For Synthesizing Sodium 5,5-Diphenylhydantoin-3-Ylmethylphosphate As Prodrug
    参考文献:China]

    93360-08-8 = 92134-98-0
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium,Carbon Solvents: Methanol; 5 H,35 °C1.2 Reagents: Sodium Hydroxide Solvents: Water; 45 Min,30 °C
    标题:Process For Preparing Fosphenytoin
    参考文献:United States]

    93390-81-9 = 92134-98-0
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Ethanol,Water; 1 H,Ph 10 - 11,10 - 15 °C
    标题:Preparation Of Fosphenytoin Sodium Heptahydrate
    参考文献:China]

    = 92134-98-0 [标题:Reaction Conditions
    标题:Phenytoin Prodrugs. Iii: Water-Soluble Prodrugs For Oral And/or Parenteral Use
    作者:Varia,S. A.; Schuller,S.; Sloan,K. B.; Stella,V. J.
    参考文献:Journal Of Pharmaceutical Sciences 日期:1984 卷标:73(8) 页码:1068-73

海关参考信息

专利信息


专利号:US-2011040105-A1
优先权日:2008-04-16
标题 :Processes useful for the synthesis of (r)-1--2-methyl-pyrrolidine
发明人:HUBER CHRISTIAN H; KHULMAN YOUNG MI; TANDEL SAGUN K; JOHANNSEN STEPHEN R; WANG TINGMIN; ANGELL PAUL
权利人:ARENA PHARM INC
摘要:Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.

专利号:WO-2019018655-A1
优先权日:2017-07-19
标题:SYNTHESIS OF BIOCOMPATIBLE TRITYLE RADICALS FOR APPLICATIONS AS HYPERPOLARIZATION AGENTS
发明人:DRIESSCHAERT BENOIT; KHRAMTSOV VALERY
权利人:UNIV WEST VIRGINIA
摘要:The present invention provides compositions and methods relating to paramagnetic probes for EPR spectroscopy. The present invention provides compositions and methods for biocompatible paramagnetic probes that can be targeted to a target in vitro or in vivo, and can provide a monofunctional or multifunctional measurement of a number of physiological parameters of cells or tissue. in vitro or in vivo, individually or in combination. The invention further relates to methods of using the compositions created by the methods of the invention.

专利号:US-2010137244-A1
优先权日:2006-07-13
标题 :Preparation and utility of hmg-coa reductase inhibitors
发明人:GANT THOMAS G; SARSHAR SEPEHR
权利人:AUSPEX PHARMACEUTICALS INC
摘要:Chemical syntheses and medical uses of novel modulators of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and diastereomeric mixtures of isomers, individual diastereomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of hypercholesterolemia, dyslipidemia, coronary artery disease, atherosclerosis, metabolic syndrome, a hyperproliferative disease such as colorectal cancer, prostate cancer, and melanoma, a neurodegenerative disease such as cerebral ischemia, Alzheimer's disease, and Parkinson's disease are described.

专利号:US-8551996-B2
优先权日:2009-02-20
标题 :Compounds, compositions, methods of synthesis, and methods of treatment
发明人:STEHOUWER JEFF; GOODMAN MARK; KILTS CLINT; NEMEROFF CHARLES
权利人:STEHOUWER JEFF; GOODMAN MARK; KILTS CLINT; NEMEROFF CHARLES; UNIV EMORY
摘要:Briefly described, embodiments of this disclosure include compounds as described herein, labeled compounds as described herein, pharmaceutical composition including compounds described herein, methods of imaging, method of forming a compound as described herein, and the like. In particular, embodiments of the disclosure include a series of triamino-pyridine derivatives and labeled triamino-pyridine derivatives, methods of synthesizing these compounds, intermediate compounds, methods of treatment using these compounds, methods of imaging, diagnosing, localizing, monitoring, and/or assessing a condition (e.g., corticotropin releasing factor type-1 (CRF1)) and/or related biological events, using triamino-pyridine derivatives, and the like. In addition, the present disclosure includes compositions (e.g., labeled triamino-pyridine derivatives that are ligands for the CRF1 receptor) used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging or SPECT imaging).

专利号:US-10092579-B2
优先权日:2016-01-07
标题:Gold(I) complexes with anticancer properties and methods of use thereof
发明人:ALTAF MUHAMMAD; MONIM-UL-MEHBOOB MUHAMMAD; ISAB ANVARHUSEIN ABDULKADIR; ALTUWAIJRI SALEH
权利人:UNIV KING FAHD PET & MINERALS
摘要:Monomeric and dimeric gold(I) complexes as anticancer agents. The gold(I) complexes are coordinated to mixed ligands: one phosphine-based ligand that may be monodentate or bidentate and at least one dithiocarbamate-based ligand that is monodentate. Pharmaceutical compositions incorporating the gold(I) complexes, methods of synthesis, methods of treating cancer and methods of inhibiting cancer cell proliferation and inducing cancer cell apoptosis are also provided.

专利号:WO-9741132-A1
优先权日:1996-04-30
标 题 :Improved process for the synthesis of diesters of phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Kaucher KA, Acquisto NM, Rao GG, Kaufman DC, Huntress JD, Forrest A, Haas CE. Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers. Pharmacotherapy. 2015 May;35(5):482-8. doi: 10.1002/phar.1589. doi: 10.1007/s13318-012-0105-x. Epub 2012 Sep 12.
3: Tanaka J, Kasai H, Shimizu K, Shimasaki S, Kumagai Y. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers. Eur J Clin Pharmacol. 2013 Mar;69(3):489-97. doi: 10.1007/s00228-012-1373-8. Epub 2012 Aug 24.
4: Voytko SM, Farrington E. Fosphenytoin sodium: new drug to replace intravenous phenytoin sodium. Pediatr Nurs. 1997 Sep-Oct;23(5):503-6. Review.

合成参考文献


参考文献:10.1016/s0960-894x(99)00294-2
摘要:Bosch J, Roca T, Domènech J, Suriol M. Synthesis of water-soluble phenytoin prodrugs. Bioorganic & Medicinal Chemistry Letters. 1999 Jul;9(13):1859–62. doi: 10.1016/s0960-894x(99)00294-2.
参考文献:10.1023/b:joms.0000021518.60670.10
摘要:Berman A. Reducing Medication Errors Through Naming, Labeling, and Packaging. Journal of Medical Systems. 2004 Feb;28(1):9–29. doi: 10.1023/b:joms.0000021518.60670.10.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知